Global Hepatitis Report, 2017. World Health Organization (WHO). 2017 http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50:892–923.

Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

Article  PubMed  Google Scholar 

European Association for the Study of the Liver EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

Article  Google Scholar 

Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

Article  CAS  PubMed  Google Scholar 

Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95.

Article  PubMed  Google Scholar 

Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.

Article  PubMed  Google Scholar 

Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325–32.

Article  CAS  PubMed  Google Scholar 

Suzuki F, Hosaka T, Imaizumi M, et al. Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Hepatol Res. 2021;51:426–35.

Article  CAS  PubMed  Google Scholar 

Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361–70.

Article  CAS  PubMed  Google Scholar 

Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. J Gastroenterol. 2019;54:182–93.

Article  CAS  PubMed  Google Scholar 

Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694–701.

Article  PubMed  Google Scholar 

Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192–9.

Article  CAS  PubMed  Google Scholar 

Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923–31.

Article  CAS  PubMed  Google Scholar 

Seto WK, Cheung KS, Wong DK, et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol. 2016;51:487–95.

Article  CAS  PubMed  Google Scholar 

Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol. 2021;75:302–10.

Article  CAS  PubMed  Google Scholar 

Kim MA, Kim SU, Sinn DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut. 2020;69:2214–22.

Article  CAS  PubMed  Google Scholar 

Arase Y, Suzuki F, Suzuki Y, et al. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007;50:161–5.

Article  CAS  PubMed  Google Scholar 

Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2012;54:88–90.

Article  CAS  PubMed  Google Scholar 

Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat. 2003;10:324–30.

Article  CAS  PubMed  Google Scholar 

Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27–33.

Article  PubMed  Google Scholar 

Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus corerelated antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. J Hepatol. 2011;55:1121–31.

Article  PubMed  Google Scholar 

Testoni B, Lebosse F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615–25.

Article  CAS  PubMed  Google Scholar 

Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019;49:457–71 (Erratum in: Aliment Pharmacol Ther 2019;50:234–5).

Article  CAS  PubMed  Google Scholar 

Hosaka T, Suzuki F, Kobayashi M, et al. Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir. Hepatol Commun. 2022;6:36–49.

Article  CAS  PubMed  Google Scholar 

Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol. 2022;57:828–37.

Article  PubMed  Google Scholar 

Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut. 2021;70:775–83.

Article  PubMed  Google Scholar 

Chang X, Li Y, Sun C, et al. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2023;58:481–93.

Article  CAS  PubMed  Google Scholar